XXXX : novel treatments for @entity1442 .

@entity1 @entity137 @entity5 @entity2816 @entity1358 @entity1442 @entity3 @entity1199 @entity3027 @entity2359
PURPOSE OF REVIEW: @entity1199 or @entity3027 induce remissions and prolong life in @entity1 carefully selected for a possibly toxic treatment. However, there is a need for better-tolerated and more effective therapies, especially in @entity1 with co-morbidities and those resistant to systemic immunotherapy. Recent achievements in the treatment of advanced @entity1358 highlight potentially significant improvements. RECENT FINDINGS: Cytoreductive surgery or radiation of metastases seems beneficial in well-selected @entity1 , especially as immunotherapy is available. Immune cells within the @entity5 correlate with response and survival, indicating the importance of local immune modulation. Such modulation has allowed the introduction of well-tolerated treatments such as the inhalation of @entity1199 to control lung metastases, which results in a significant survival benefit for high-risk @entity1 , as suggested by a recent outcome study in 200 patients. Antibody-based @entity5 targeting against cG250, specifically expressed on @entity1358 , seems to stabilize progressive @entity3 and does not induce @entity137 . Vaccination strategies are also well tolerated, but have not yet shown convincing results in @entity1442 . Other approaches have not fulfilled expectations. @entity2816 has significant @entity2359 and its efficacy was not confirmed in recent studies. Stem cell transplantation has significant @entity137 , and cannot yet be recommended, but may have future potential. SUMMARY: Cytokine-based immunotherapy can now be considered standard in the treatment of @entity1358 . There is good evidence that additional local procedures such as surgery, radiation or the inhalation of @entity1199 improve response and survival in @entity3 with moderate @entity137 , resulting in a significant improvement for @entity1 suitable for these approaches.
